MADELYN PALMER: Open Payments
NPI 1417928649 · KAMAS, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$892 in 43 payments from 19 companies in 2025. Trend: 2023 $1,525 · 2024 $1,416 · 2025 $892
Food & beverage: $892
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 10 | $239 |
| Novo Nordisk Inc | 5 | $102 |
| PFIZER INC. | 5 | $100 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $58 |
| Lilly USA, LLC | 3 | $56 |
| Exact Sciences Corporation | 2 | $40 |
| Merck Sharp & Dohme LLC | 2 | $37 |
| Vanda Pharmaceuticals Inc. | 1 | $33 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| Amgen Inc. | 1 | $28 |
Products named: VRAYLAR, UBRELVY, Wegovy, NURTEC ODT, Kerendia, QULIPTA, GARDASIL 9, FANAPT.
Industry payments across UT — which companies pay providers there.
